Current filters:  
USA
Cannabis
United States
Duane Morris LLP
On Friday, April 23, 1999, the lights went out in Times Square—and in countless locations coast to coast—for tobacco advertising. That was the date by which the largest tobacco companies...
Seyfarth Shaw LLP
Welcome back to The Week in Weed, your Friday look at what's happening in the world of legalized marijuana.
Arnold & Porter
Howard Sklamberg, Life Sciences & Healthcare Regulatory partner and former FDA Deputy Commissioner, was recently a guest on NPR's podcast 1A for its episode...
McDonald Hopkins
On April 30, 2024 the Associated Press reported that the U.S. Drug Enforcement Administration (DEA) submitted a proposal to the White House Office of Management and Budget (OMB)...
Sheppard Mullin Richter & Hampton
In a much-anticipated move, sources recently reported that the Drug Enforcement Administration ("DEA") will recommend rescheduling cannabis...
Plunkett & Cooney
It is estimated that medical and recreational cannabis sales could exceed $33.6 billion with an additional economic impact of $100.8 billion by the end of 2023.
Seyfarth Shaw LLP
Welcome back to The Week in Weed, your Friday look at what's happening in the world of legalized marijuana. In what's probably the biggest news in cannabis since Canada legalized...
Reavis Page Jump LLP
The saga of the New York LLC Transparency Act keeps changing. As the Governor recently signed a new law changing several key provisions of the Act, this article will serve to supplement our article...
Pierson Ferdinand
Yesterday, I wrote about how the DEA's move to ease restrictions on marijuana would change the ADA landscape for employers by requiring accommodations for employees with disabilities...
Duane Morris LLP
New Jersey Governor Murphy announced yesterday that current NJCRC Executive Director Jeff Brown is returning to the New Jersey Department of Health to take on the role of Deputy Commissioner for Healthcare Systems, effective May 20, 2024.
Sheppard Mullin Richter & Hampton
On August 29, 2023, the U.S. Department of Health and Human Services (HHS) made a groundbreaking recommendation to the Drug Enforcement Administration (DEA) – that cannabis should be rescheduled...
Lowenstein Sandler
The U.S. Drug Enforcement Administration (DEA) is on the brink of reclassifying marijuana, marking a watershed moment in American drug policy.
Ogletree, Deakins, Nash, Smoak & Stewart
In the homestretch of Minnesota's 2024 legislative session, tension has mounted in St. Paul as state House and Senate committees scramble to secure enough votes...
Duane Morris LLP
Seth Goldberg, partner and team lead of Duane Morris' Cannabis Industry Group, spoke with The American Lawyer about how the firm is preparing for cannabis rescheduling.
Jackson Lewis
The U.S. Drug Enforcement Administration will recommend that marijuana should be rescheduled from a Schedule I drug to a Schedule III drug, according to an announcement made April 30, 2024...
Duane Morris LLP
Multiple news sources reported today that the DEA will be recommending rescheduling cannabis to a Schedule III drug.
Michael Best & Friedrich
This Historic federal action would recognize medical benefits of cannabis, open the door for more research, and be a significant change for the industry.
Seyfarth Shaw LLP
Cannabis would move to Schedule III from Schedule I under this reclassification. In a move long awaited by the cannabis industry, the Drug Enforcement Administration (DEA)...
McGlinchey Stafford
Marking a significant development for the cannabis industry both in the state of Florida and throughout the U.S., an initiative will appear on the November 5, 2024...
McGlinchey Stafford
After fifty years, the federal government finally acknowledged that marijuana has medical value and is not as dangerous as heroin. As first reported by the Associated Press...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Related Topics
Popular Contributors
Upcoming Events
Mondaq Social Media